




RealRate

PHARMACEUTICAL 2018

Syndax Pharmaceuticals Inc
Rank 134 of 332

Syndax



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 92% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 300%, being 48% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	133,442
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,798
Liabilities, Non-Current	17,069
Other Assets	3,477
Other Compr. Net Income	-199
Other Expenses	0
Other Liabilities	0
Other Net Income	3,260
Other Revenues	0
Property and Equipment	267
Research and Development	48,201
Selling, General and Administrative Expense	15,861

Output Variable	Value in 1000 USD
Assets	137,186
Liabilities	32,867
Expenses	64,062
Revenues	0
Stockholders Equity	104,319
Net Income	-60,802
Comprehensive Net Income	-60,902
BaseVar	118,787
ECR before LimitedLiability	196%
Economic Capital Ratio	300%